|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$388,700
|
N/A
|
National Institutes of Health
|
|
IGF::OT::IGF Topic 378: mPROS: Mobile PRO-CTCAE Administration System for Post-Radiation Toxicities
|
261201800013C
|
$224,995
|
$112,498
|
-, -
|
INTELLIGENT AUTOMATION, INC.
|
|
NCI AT FREDERICK IAA WITH DEFENSE BIOLOGICAL PRODUCT ASSURANCE OFFICE (DBPAO)
|
ACO18006-001
|
$1,367
|
$1,367
|
-, -
|
UNITED STATES DEPARTMENT OF DE
|
|
IAA WITH VA FOR PREDICTION TOOLS FOR HEAD AND NECK CANCERS
|
APC18006-001
|
$15,000
|
$15,000
|
-, -
|
VETERANS HEALTH ADMINISTRATION
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
A biomarker-driven strategy to guide the use of radiotherapy in non-small cell lung cancer
|
1R37CA222294-01A1
|
$366,000
|
|
ABAZEED, MOHAMED
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Novel platform linking cancer-specific glycosylation with cell signaling outcomes
|
1R21CA229044-01
|
$225,250
|
|
ABBOTT, KAREN
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
Identifying molecular drivers of tumor heterogeneity in pancreatic cancer
|
1F31CA224792-01A1
|
$36,672
|
|
ADAMS, CHRISTINA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
University of North Carolina Womens Interagency HIV Study UNC WIHS
|
3U01AI103390-05S1
|
$60,652
|
|
ADIMORA, ADAORA
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
|
1R01CA236615-01
|
$392,764
|
|
ADUSUMILLI, PRASAD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Developing targeted activatable peptides to amplify radiosensitizer delivery
|
5R03CA219744-02
|
$77,500
|
$77,500
|
ADVANI, SUNIL
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Quantitative Radiomics System Decoding the Tumor Phenotype
|
5U24CA194354-04
|
$683,694
|
$341,847
|
AERTS, HUGO
|
DANA-FARBER CANCER INST
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Genetics of Graft-versus-Host Disease
|
1R01CA231141-01
|
$265,229
|
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-05S1
|
$94,087
|
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
$7,268
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
$46,110
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Functional Determinants of Metastatic Dormancy
|
5R01CA109182-15
|
$423,844
|
$423,844
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Epigenetic and microenvironmental regulation of dormant disseminated cancer
|
5R01CA218024-02
|
$428,136
|
$428,136
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
|
5R01CA134633-06
|
$535,071
|
$535,071
|
AHRENS, ERIC
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
|
1P01CA217805-01A1
|
$2,105,511
|
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
$36,709
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Chemically produced neural progenitors loaded with ferumoxide-protamine sulfate complex for visualization of gliomas
|
1R43CA228726-01A1
|
$300,000
|
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Inherited bone marrow failure syndromes study
|
ZIA CP010144 07130
|
$1,652,758
|
$462,773
|
Alter, Blanche
|
DCEG (NCI)
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
$1,425
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
$2,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
$26,456
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma
|
1R01CA222931-01A1
|
$370,575
|
|
AMENGUAL, JENNIFER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Functional Contribution of Metabolic Complex to Cancer Cell Metabolism
|
1R03CA219609-01A1
|
$72,194
|
|
AN, SONGON
|
UNIVERSITY OF MARYLAND BALT CO CAMPUS
|
|
Womens Interagency HIV Study (WIHS-V)
|
3U01AI035004-25S1
|
$144,370
|
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-05
|
$701,988
|
$14,040
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Steroid hormone regulation of immune responses
|
1R01CA229400-01
|
$384,018
|
|
ANDERSON, ANA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Resource stratified phased implementation frameworks to improve breast healthcare
|
1R13CA224776-01A1
|
$50,000
|
|
ANDERSON, BENJAMIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
|
1U01CA232382-01
|
$688,043
|
|
ANDERSON, ALEXANDER
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Cancer Metabolism Training Program
|
1T32CA221709-01A1
|
$201,444
|
|
ANN, DAVID
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients
|
3R01CA201124-03S1
|
$189,200
|
|
ANTONIA, SCOTT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
|
2R01CA160495-06A1
|
$370,500
|
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-05
|
$605,293
|
$30,265
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Development of an MRI-compatible, High-Frequency Irreversible Electroporation (H-FIRE) System for Non-thermal Ablation of Inoperable Brain Tumors
|
1R43CA233158-01
|
$244,498
|
|
ARENA, CHRISTOPHER
|
VOLTMED, INC.
|
|
COMPRENDO: Adaptation and Implementation of a Peer-Navigation Intervention to Improve Research Literacy and Diversity in Pediatric Leukemia Clinical Trials
|
1K08CA230306-01
|
$254,821
|
|
ARISTIZABAL, PAULA
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Cancer Genetics of Short Telomere Syndromes
|
1R01CA225027-01A1
|
$530,521
|
|
ARMANIOS, MARY
|
JOHNS HOPKINS UNIVERSITY
|
|
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
|
2R01CA176745-07
|
$404,076
|
|
ARMSTRONG, SCOTT
|
DANA-FARBER CANCER INST
|
|
Predicting the Presence of Clinically Significant Prostate Cancer using Multiparametric MRI and MR-US Fusion Biopsy
|
1R21CA220352-01A1
|
$195,568
|
|
ARNOLD, COREY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
|
1R01CA231219-01
|
$444,969
|
|
ARONSON, WILLIAM
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
$2,485
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
$1,715
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
$33,345
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
Total relevant funding to Head and Neck for this search: $65,694,493
|